论文部分内容阅读
目的 评价阿莫西林克拉维酸钾(4:1)分散片口服治疗小儿细菌性肺炎的安全性,为临床治疗提供依据。方法将68例确诊的细菌性肺炎患儿随机分成治疗组与对照组,治疗组采用口服阿莫西林克拉维酸钾(4:1)分散片治疗;对照组采用阿莫西林克拉维酸钾序贯治疗(先静脉滴注3~4 d后再换用阿莫西林克拉维酸钾(4:1)分散片口服),两组总疗程均为10~14 d。结果治疗组与对照组总有效率分别为91.4%和93.9%,两组对照差异无统计学意义(P>0.05)。结论阿莫西林克拉维酸钾(4:1)分散片口服治疗小儿细菌性肺炎具有安全、有效、经济、痛苦小、患儿易接受等优点,值得临床推广应用。
Objective To evaluate the safety of amoxicillin and clavulanate potassium (4: 1) dispersible tablets in the treatment of bacterial pneumonia in children and provide the basis for clinical treatment. Methods Sixty-eight children diagnosed with bacterial pneumonia were randomly divided into treatment group and control group. The treatment group was treated with oral amoxicillin and potassium clavulanate (4: 1) dispersible tablets. The control group was treated with amoxicillin potassium clavulanate Treatment (first intravenous infusion of 3 ~ 4 days and then switch to amoxicillin potassium clavulanate (4: 1) dispersible tablets orally), the two groups were treated for 10 ~ 14 d. Results The total effective rates of the treatment group and the control group were 91.4% and 93.9% respectively, with no significant difference between the two groups (P> 0.05). Conclusion Amoxicillin potassium clavulanate (4: 1) dispersible tablets oral treatment of bacterial pneumonia in children is safe, effective, economical, painless, easy to accept the advantages of children, it is worth promoting the clinical application.